RE: Tech transfer complete1 Apr 2026 10:40
Pumpky and others who haven't done the required reading....re-read this paragraph ""the infused CAR-T cells engage their antigen receptors, become activated, and rapidly proliferate through antigen-driven expansion. This self-amplifying process allows the CAR-T population to increase dramatically in number in vivo, enabling even a lower starting dose to generate a robust effector pool that serially kills tumor cells, potentially leading to deep remissions or curative outcomes as the amplified cells continue to patrol and eliminate residual disease."
This is why P1-3 doesn't need another dose...it self-amplifies / multiplies - it just takes a little longer for this to happen. The higher dose ought to lead to faster blast reduction and in the absence of any adverse reactions would be better.